A5104506506- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- Autoimmune and Inflammatory Disorders Research
- Bone and Joint Diseases
- Systemic Lupus Erythematosus Research
- Spine and Intervertebral Disc Pathology
- Lymphoma Diagnosis and Treatment
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Chronic Lymphocytic Leukemia Research
- Musculoskeletal synovial abnormalities and treatments
- Biosimilars and Bioanalytical Methods
- Health Systems, Economic Evaluations, Quality of Life
- Osteoarthritis Treatment and Mechanisms
- Musculoskeletal pain and rehabilitation
- Monoclonal and Polyclonal Antibodies Research
- Peripheral Neuropathies and Disorders
- Scoliosis diagnosis and treatment
- Orthopedic Surgery and Rehabilitation
- Systemic Sclerosis and Related Diseases
- Inflammasome and immune disorders
- Viral Infections and Immunology Research
- Inflammatory mediators and NSAID effects
- Inflammatory Bowel Disease
- Gout, Hyperuricemia, Uric Acid
Diakonhjemmet Hospital
2016-2025
Leiden University Medical Center
2016-2025
Leiden University
2014-2025
Ruhr University Bochum
2011-2024
Center for Rheumatology
2011-2024
Oregon Health & Science University
2014-2024
Rheumazentrum Ruhrgebiet
2002-2024
AbbVie (United States)
2014-2024
University of Alberta
2009-2024
VIB-UGent Center for Inflammation Research
2019-2024
<h3>Objective:</h3> To validate and refine two sets of candidate criteria for the classification/diagnosis axial spondyloarthritis (SpA). <h3>Methods:</h3> All Assessment SpondyloArthritis international Society (ASAS) members were invited to include consecutively new patients with chronic (⩾3 months) back pain unknown origin that began before 45 years age. The first tested in entire cohort 649 from 25 centres, then refined a random selection 40% cases thereafter validated remaining 60%....
Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces the symptoms and signs rheumatoid arthritis. However, capacity this approach effect a more sustained benefit its on joint damage are not known.
To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for most recent developments in field.An international task force considered new evidence supporting or contradicting previous and novel therapies strategic insights based on two systematic literature searches efficacy safety disease-modifying antirheumatic drugs (DMARDs) since last (2016) until 2019. A predefined voting process was applied, current levels...
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs bDMARDs, respectively) have been updated. The 2013 update has developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each sDMARDs, including glucocorticoids, bDMARDs safety aspects DMARD therapy); treatment...
The field of spondyloarthritis (SpA) has experienced major progress in the last decade, especially with regard to new treatments, earlier diagnosis, imaging technology and a better definition outcome parameters for clinical trials. In present work, Assessment SpondyloArthritis international Society (ASAS) provides comprehensive handbook on most relevant aspects assessments spondyloarthritis, covering classification criteria, MRI <i>x</i> rays sacroiliac joints spine, complete set all...
Abstract Objective To compare the benefits of initiating treatment with methotrexate (MTX) and infliximab (anti–tumor necrosis factor α [anti‐TNFα] monoclonal antibody) those MTX alone in patients rheumatoid arthritis (RA) ≤3 years' duration. Methods RA were eligible if they had active disease no prior or a TNFα inhibitor. One thousand forty‐nine randomly assigned 4:5:5 ratio to 3 groups: MTX–placebo, MTX–3 mg/kg infliximab, MTX–6 infliximab. dosages rapidly escalated 20 mg/week, placebo...
<h3>Objectives</h3> To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing most recent developments in field. <h3>Methods</h3> An international task force was formed and solicited three systematic literature research activities on safety efficacy disease-modifying antirheumatic drugs (DMARDs) glucocorticoids (GCs). The new evidence discussed light last from 2019. A predefined voting process applied to each overarching principle recommendation....
An investigation of clinical and laboratory variables which might form the basis for judging disease activity in practice was made by six rheumatologists a prospective study up to three years9 duration 113 patients with early rheumatoid arthritis. Decisions start treatment slow acting antirheumatic drugs were equated moments high activity. If not started or if drug remained unchanged at least one year stopped because remission, this periods low Two groups, according above criteria, formed....
Objectives: To develop a new index for disease activity in ankylosing spondylitis (ASDAS) that is truthful, discriminative and feasible, includes domains/items are considered relevant by patients doctors. Methods: Eleven candidate variables covering six domains of activity, selected ASAS experts Delphi exercise, were tested three-step approach, similar to the methodology used score rheumatoid arthritis. Data on 708 included ISSAS (International Study Starting tumour necrosis factor blocking...
Background Since the publication of European League Against Rheumatism recommendations for pharmacological treatment psoriatic arthritis (PsA) in 2012, new evidence and therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review performed regarding PsA. Subsequently, were formulated based on expert opinion 34 Task Force members. Levels strengths allocated. Results updated comprise 5 overarching principles 10 recommendations,...
<h3>Objective:</h3> Non-radiographic axial spondyloarthritis (SpA) is characterised by a lack of definitive radiographic sacroiliitis and considered an early stage ankylosing spondylitis. The objective this study was to develop candidate classification criteria for SpA that include patients with but also without sacroiliitis. <h3>Methods:</h3> Seventy-one possible SpA, most whom were lacking definite sacroiliitis, reviewed as "paper patients" 20 experts from the Assessment SpondyloArthritis...
To evaluate the safety and efficacy of adalimumab, a fully human recombinant IgG1 monoclonal antibody that specifically targets tumor necrosis factor, in patients with active ankylosing spondylitis (AS).This was multicenter, randomized (2:1 ratio), double-blind, placebo-controlled study to subcutaneous injection 40 mg every other week, compared placebo for 24 weeks. The primary end point percentage 20% response according ASsessment Ankylosing Spondylitis International Working Group criteria...
<h3>Background:</h3> Magnetic resonance imaging (MRI) of sacroiliac joints has evolved as the most relevant modality for diagnosis and classification early axial spondyloarthritis (SpA) including ankylosing spondylitis. <h3>Objectives:</h3> To identify describe MRI findings in sacroiliitis to reach consensus on which are essential definition sacroiliitis. <h3>Methods:</h3> Ten doctors (two radiologists eight rheumatologists) from ASAS/OMERACT working group reviewed discussed three workshops...
To update the European League Against Rheumatism (EULAR) recommendations for pharmacological treatment of psoriatic arthritis (PsA).According to EULAR standardised operating procedures, a systematic literature review was followed by consensus meeting develop this involving 28 international taskforce members in May 2019. Levels evidence and strengths were determined.The updated comprise 6 overarching principles 12 recommendations. The address nature PsA diversity both musculoskeletal...
The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs in quite a number patients. Tumor necrosis factor inhibitors have demonstrated success reducing AS disease activity limited clinical trials. objective this multicenter, randomized, placebo-controlled study was evaluate the efficacy safety infliximab patients with AS.Patients were randomly assigned receive infusions placebo...
Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in patients with rheumatoid arthritis.We conducted a 52-week, phase 3, double-blind, placebo- active-controlled trial which 1307 active arthritis who were receiving background therapy methotrexate randomly assigned to one three regimens 3:3:2 ratio: placebo (switched baricitinib after 24 weeks), 4 mg once daily, or 40 adalimumab (an anti-tumor necrosis factor α monoclonal antibody)...